2023 World Conference on Lung Cancer (Posters)-EP12.01. Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study

EP12.01. Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the safety and efficacy of aumolertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who were intolerant to osimertinib treatment. The study included 15 patients who experienced adverse reactions (AEs) after osimertinib treatment and subsequently received aumolertinib. <br /><br />The primary endpoint of the study was the 3-month conversion success rate, defined as the proportion of patients who did not experience grade 2 hematologic toxicity or grade 3 other adverse events within 3 months of switching to aumolertinib. The secondary endpoints included objective remission rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) for aumolertinib treatment.<br /><br />At the data cut-off, the 3-month conversion success rate was 100%, indicating that all patients tolerated aumolertinib well. The overall ORR was 80%, with 2 complete responses and 10 partial responses. The DCR was 100%. Subgroup analysis showed that patients who experienced rash and diarrhea as AEs after osimertinib treatment had ORRs of 87.5% and 100% respectively.<br /><br />During aumolertinib treatment, only two patients experienced grade 1 AEs, specifically diarrhea and mouth ulceration. No other AEs were observed. The median PFS has not been reached at the time of the analysis.<br /><br />These findings suggest that aumolertinib is a safe and effective treatment option for patients with EGFR-mutant advanced NSCLC who are intolerant to osimertinib, particularly for those who experienced rash and diarrhea as AEs. The study highlights the importance of timely intervention and standardized treatment for patients who experience AEs after osimertinib, as well as the potential benefits of switching between different third-generation EGFR-TKIs to improve patient compliance, quality of life, and survival outcomes.

Asset Subtitle

Biao Yao

Meta Tag

Speaker Biao Yao

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

aumolertinib

EGFR-TKI

EGFR-mutant

non-small cell lung cancer

osimertinib

adverse reactions

conversion success rate

objective remission rate

disease control rate

progression-free survival